Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure:Effects On Endothelial Function, Left Ventricular Remodelling, Natriuretic Peptide Levels, And Exercise Capacity.

Trial Profile

Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure:Effects On Endothelial Function, Left Ventricular Remodelling, Natriuretic Peptide Levels, And Exercise Capacity.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Jul 2010

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Chronic heart failure
  • Focus Pharmacodynamics
  • Acronyms n3-PUFA-HF
  • Most Recent Events

    • 12 Jul 2010 Actual initiation date (Sep 2005) added, additional trial acronym n3-PUFA-HF identified as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top